Hint mode is switched on Switch off
Cbonds API
Integrate prices, fundamentals and corporate actions into your workflow

Get Global Stock Data via API

  • Prices & history
  • Fundamentals
  • Dividends & corporate actions

Helus Pharma, ordinary share
HELP, CA4234921076

FIND, SAVE & TRACK INVESTMENTS WITH CBONDS WATCHLIST

With Cbonds Watchlist you can always stay updated on your investments to make conscious decisions!

Watchlist
You need to request access
Add a stock to WL
Choose all Reset all
Save Close
Helus Pharma, сountry — Canada
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Latest quotes

Try in 7-days Trial access

  • Get full online access to the database
  • Use our powerful bond screener
  • Track bond prices from 400+ sources
  • Smart Portfolio Monitoring
Unlock Data
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Helus Pharma Inc., formerly Cybin Inc., is a Canada-based clinical stage pharmaceutical company. It is developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. The Company's proprietary NSAs are ...
Helus Pharma Inc., formerly Cybin Inc., is a Canada-based clinical stage pharmaceutical company. It is developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. The Company's proprietary NSAs are intended to address the unmet need for people who suffer from depression, anxiety, and other mental health conditions. The Company is developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. It is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. It has developed EMBARK, which incorporates evidence-based therapies (EBTs), empirically supported treatments (ESTs), and provides session monitors with the training needed to support participants safely and effectively through treatment sessions in clinical trials. Its other pipeline product in development is HLP005.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Helus Pharma Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Indicators

IFRS/US GAAP reports

  • 2026

  • 2025

  • 2024

  • 2023

    • News

    All organization news

    Holders

    Related Stock indices

    • NASDAQ Composite
      25,955.34
      Value
      23/10/2026
      Date

    Industry Leaders

    Registration is required to get access.